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A B S T R A C T   
Exposure to hepatitis E virus (HEV) bears a high risk of developing chronic infection in immunocompromised 
patients, including organ transplant recipients and cancer patients. We aim to identify effective anti-HEV ther-
apies through screening and repurposing safe-in-human broad-spectrum antiviral agents. In this study, a safe-in- 
human broad-spectrum antiviral drug library comprising of 94 agents was used. Upon screening, we identified 
gemcitabine, a widely used anti-cancer drug, as a potent inhibitor of HEV replication. The antiviral effect was 
confirmed in a range of cell culture models with genotype 1 and 3 HEV strains. As a cytidine analog, exogenous 
supplementation of pyrimidine nucleosides effectively reversed the antiviral activity of gemcitabine, but the level 
of pyrimidine nucleosides per se does not affect HEV replication. Surprisingly, similar to interferon-alpha (IFNα) 
treatment, gemcitabine activates STAT1 phosphorylation. This subsequently triggers activation of interferon- 
sensitive response element (ISRE) and transcription of interferon-stimulated genes (ISGs). Cytidine or uridine 
effectively inhibits gemcitabine-induced activation of ISRE and ISGs. As expected, JAK inhibitor 1 blocked IFNα, 
but not gemcitabine-induced STAT1 phosphorylation, ISRE/ISG activation, and anti-HEV activity. These effects 
of gemcitabine were completely lost in STAT1 knockout cells. In summary, gemcitabine potently inhibits HEV 
replication by triggering interferon-like response through STAT1 phosphorylation but independent of Janus 
kinases. This represents a non-canonical antiviral mechanism, which utilizes the innate defense machinery that is 
distinct from the classical interferon response. These results support repurposing gemcitabine for treating hep-
atitis E, especially for HEV-infected cancer patients, leading to dual anti-cancer and antiviral effects.   
1. Introduction 
Hepatitis E virus (HEV), a single-stranded positive-sense RNA virus, 
is the most common cause of acute viral hepatitis worldwide. Globally, it 
is recently estimated that over 900 million corresponding to 1 in 8 in-
dividuals have ever experienced HEV infection. Among those, 15–110 
million individuals have recent or ongoing HEV infection (Li et al., 
2020). Among the eight classified genotypes, genotype 1 and 2 HEV 
exclusively infect humans mainly prevalent in developing countries 
responsible for many water-borne outbreaks. In contrast, genotype 3 and 
4 HEV are zoonotic, causing sporadic cases mostly seen in the western 
world (Zhou et al., 2019). 
Although HEV infection is usually acute and self-limiting in healthy 
individuals, it can cause severe morbidity and even mortality in special 
populations. Acute infection with genotype 1 HEV in pregnant women 
imposes a high risk of developing fulminant hepatic failure, leading to a 
high death rate of up to 30% (Hakim et al., 2017). Infection with ge-
notype 3 and occasionally genotype 4 HEV in immunocompromised 
patients is prone to develop chronic hepatitis E. This has been 
well-recognized in organ transplant recipients, as they universally 
receive immunosuppressive medication (Kamar et al., 2008; Wang et al., 
2018; Zhou et al., 2013). Cancer patients, especially those undergoing 
chemotherapy or radiotherapy, also have a compromised immune sys-
tem, and have been reported to develop chronic HEV infection (Fuse 
et al., 2015; Protin et al., 2019; Tavitian et al., 2010; von Felden et al., 
2019). Although no FDA-approved medication is available, the general 
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antiviral drugs including interferon alpha (IFNα), ribavirin, or their 
combination have been repurposed as off-label treatment for chronic 
hepatitis E (Debing et al., 2016; Haagsma et al., 2010; Kamar et al., 
2010a, 2010b). Although ribavirin monotherapy is effective in a sub-
stantial proportion of treated patients, treatment failure does occur in a 
subset of patients. Furthermore, many patients are not eligible or do not 
tolerate IFNα or ribavirin treatment (Debing et al., 2014; Pischke et al., 
2013; Rostaing et al., 1995). Thus, there is a clinical need for further 
developing new antiviral therapies against HEV. 
Development of new antiviral drugs usually takes more than ten 
years requiring enormous investment with a high risk of failure. The fact 
that only a specific population with HEV infection requires antiviral 
treatment does not justify the pharmaceutical industry to develop new 
anti-HEV drugs. Thus, we propose to systematically screen and repur-
pose the existing drugs that can be readily used in the clinic. In this 
study, we screened a library of safe-in-human broad-spectrum antiviral 
agents. These compounds are known to target viruses belonging to two 
or more viral families, and have been used in the clinic or have passed 
phase I clinical trials (Andersen et al., 2020; Ianevski et al., 2018). We 
identified gemcitabine, a widely used anti-cancer drug, potently inhibits 
HEV infection. Unexpectedly, it functions through the activation of 
interferon-like response via STAT1 phosphorylation. But the 
mechanism-of-action is distinct from the classical antiviral interferon 
response. 
2. Materials and methods 
2.1. Reagents and antibodies 
A library of 94 safe-in-man board-spectrum antiviral agents (htt 
ps://drugvirus.info) were dissolved in DMSO with a stock concentra-
tion of 10 mM. Gemcitabine, ribavirin, human IFNα, mycophenolic acid 
(MPA), cytidine, uridine, cytidine 5′-triphosphate (CTP) and uridine 5′- 
triphosphate (UTP) were purchased from Sigma-Aldrich (Zwijndrecht, 
The Netherlands) and were dissolved in 1 × PBS (Phosphate-Buffered 
Saline) with the stock concentration of 200 mM. Stocks of JAK inhibitor 
1 (SC-204021, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were 
dissolved in Dimethyl sulfoxide (DMSO, Sigma, Zwijndrecht, The 
Netherlands) with a final concentration of 5 mg/ml. The HEV ORF2 
antibody was purchased from EMD Millipore (MAB8002). Phospho- 
STAT1 (Tyr701) (58D6, Rabbit mAb, 9167) and STAT1 (Rabbit mAb, 
9172) antibodies were obtained from Cell Signaling Technology (Dan-
vers, MA, USA). β-actin antibody (mouse monoclonal, sc-47778) was 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti- 
rabbit and anti-mouse IRDye-conjugated secondary antibodies (Li-Cor 
Biosciences, Lincoln, NE, USA) were also used. 
2.2. Cell culture 
Human hepatoma Huh7 and PLC/PRF/5 (PLC) cell lines, human 
embryonic kidney epithelial cell line (293T), human glioblastoma cell 
line (U87), and Huh7-STAT1 knockout cells were kindly provided by the 
Department of Viroscience (Erasmus Medical Center) and cultured in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum, 100 IU/mL penicillin, and 100 IU/mL streptomycin. 
2.3. Viruses and cell culture models 
Genotype 3 HEV models are based on a plasmid construct containing 
the full-length HEV genome (genotype 3 Kernow-C1 p6 clone, GenBank 
accession number JQ679013) or a construct containing subgenomic 
HEV sequence in which ORF2 was replaced by a Gaussia luciferase re-
porter gene (p6-Luc). Viral RNA was produced by using the Ambion 
mMESSAGE nMACHINE in vitro RNA transcription kit. Cells were elec-
troporated with p6 full-length HEV RNA or p6-Luc subgenomic RNA to 
generate infectious or luciferase-based replicon models, respectively. 
Similarly, the genotype 1 replicon model is based on the Sar 55/S17/luc 
HEV clone containing a Gaussia luciferase reporter. 
Interferon response was monitored by the interferon-stimulated 
response element (ISRE) reporter (Huh7-ISRE-Luc). Huh7 cells were 
transduced with a lentiviral transcriptional reporter system expressing 
the firefly luciferase gene driven by a promoter containing multiple ISRE 
elements (SBI Systems Biosciences, Mountain View, CA, USA). Lucif-
erase activity indicates ISRE promoter activity. 
2.4. Virus production and re-infection assay 
Huh7 cells harboring the infectious genotype 3 HEV were seeded into 
a multi-well plates HEV particles were harvested by repeated freezing 
and thawing 3 times, and filtered by 0.45 μm filters. Naïve Huh7 cells 
were seeded into a muti-well plate and culture medium was discarded 
when cell confluence was approximately 80%, followed by twice 1 ×
PBS washing. Harvested viruses were added and incubated at 37 ̊C with 
5% CO2 for 24 h for re-infection, followed by 3 times washing with 1 ×
PBS to remove unattached viruses. Then cells were incubated with 
culture medium for another 48 h. The infectivity of produced HEV 
particles were analyzed by qRT-PCR, Western blotting, and confocal 
imaging assays, respectively. 
2.5. MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) (Sigma) was added to the cells seeded in 96-well plate and 
cells were maintain at 37 ◦C with 5% CO2 for 3 h. Medium was removed 
and 100 μL of DMSO was added to each well. The absorbance of each 
well was read on the microplate absorbance readers (BIO-RAD) at 
wavelength of 490 nm. 
2.6. Quantification of viral replication 
Viral replication in HEV replication models was monitored by the 
activity of secreted Gaussia luciferase measured by BioLux Gaussia 
Luciferase Flex Assay Kit (New England Biolabs, Ipswich, MA, USA). 
Luciferase activity was quantified with a LumiStar Optima luminescence 
counter (BMG Lab Tech, Offenburg, Germany). For HEV infectious 
model, viral RNA was quantified by SYBR-Green-based (Applied Bio-
systems SYBR Green PCR Master Mix; Thermo Fisher Scientific Life 
Sciences) real-time PCR (qRT-PCR). GAPDH was used as a housekeeping 
gene to normalize gene expression using the 2-ΔΔCt method. 
2.7. Western blot 
Proteins in cell lysates were heated at 95 ◦C for 5 min, followed by 
loading onto a 10% sodium dodecyl sulfate polyacrylamide gel (SDS- 
PAGE), separated at 90 V for 120 min, and electrophoretically trans-
ferred onto a polyvinylidene difluoride (PVDF) membrane (pore size: 
0.45 mm; Thermo Fisher Scientific Life Sciences) for 120 min with an 
electric current of 250 mA. Subsequently, the membrane was blocked 
with blocking buffer (Li-Cor Biosciences). Membrane was followed by 
incubation with primary antibodies rabbit anti-STAT1 (1:1000), anti- 
pSTAT1 (1:1000), or mouse anti-HEV ORF2 (1:1000), anti-β-actin 
(1:1000) overnight at 4 ◦C. The membrane was washed 3 times followed 
by incubation for 1 h with anti-rabbit or anti-mouse IRDye-conjugated 
secondary antibodies (1:5000; Li-Cor Biosciences) at room temperature. 
After washing 3 times, protein bands were detected with Odyssey 3.0 
Infrared Imaging System. 
2.8. Statistical analysis 
Statistical analysis was performed using the non-paired, non-para-
metric test (Mann-Whitney test; GraphPad Prism software, GraphPad 
Software Inc., La Jolla, CA). All results were presented as mean ±
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standard errors of the means (SEM). P values < .05 were considered as 
statistically significant. 
3. Results 
3.1. Screening a broad-spectrum antiviral drug library identifies 
gemcitabine as a potent anti-HEV agent 
To identify potential anti-HEV candidates, we screened a library of 
94 known safe-in-human broad-spectrum antiviral agents. Huh7 cell- 
based genotype 3 HEV replicon model (Huh7-p6-Luc) was treated 
with each compound at a concentration of 10 μM or DMSO vehicle 
control for 48 h. HEV replication-related luciferase activity and cyto-
toxicity were determined (Fig. 1A). To minimize off-target effects, 23 
candidates with over 50% inhibition on HEV luciferase activity but less 
than 50% cytotoxicity were selected for subsequent validation (Fig. 1A; 
Supplementary Table 1). Their antiviral effects were further verified in 
the full-length HEV infectious model by quantifying viral RNA using 
qRT-PCR assay (Fig. 1B). In both models, the widely used anti-cancer 
drug gemcitabine showed potent anti-HEV activity, with inhibition 
over 70%, and thus was subjected to further detailed study. 
3.2. Gemcitabine consistently inhibits HEV in a wide range of cell models 
Besides hepatitis, HEV infection associates with a broad range of 
extrahepatic manifestations. We thus further profiled the antiviral ac-
tivity of gemcitabine in a variety of cell models, including hepatic and 
non-hepatic cell lines with genotype 1 or 3 HEV. Gemcitabine treatment 
inhibited viral replication-related luciferase activity in a dose-dependent 
manner in the hepatic Huh7 cells harboring genotype 3 HEV replicon 
(Fig. 2A). The 10% inhibition and cytotoxicity (IC10 and CC10) con-
centrations of gemcitabine were 0.046 μM and 0.32 mM, 50% inhibition 
and cytotoxicity (IC50 and CC50) concentrations were 0.42 μM and 2.9 
mM, and 90% inhibition and cytotoxicity (IC90 and CC90) concentra-
tions were 3.78 μM and 26.1 mM, respectively (Fig. 2B). Consistently, 
gemcitabine significantly inhibited HEV at both viral RNA (Fig. 2C) and 
ORF2 protein (Fig. 2D) levels in Huh7 cells harboring the infectious 
genotype 3 clone. Furthermore, gemcitabine also does-dependently 
inhibited genotype 1 HEV replication (Fig. 2E). By harvesting HEV 
particles from Huh7 cells harboring the infectious genotype 3 clone at 
48 h post-treatment, we performed an re-infection assay to determine 
the relative titers of viruses by re-infecting naïve Huh7 cells. The amount 
of produced HEV with infectivity was significantly reduced by gemci-
tabine treatment (Fig. S1A). At the protein level, we found potent in-
hibition of HEV ORF2 expression determined by Western blotting 
(Fig. S1B) and confocal imaging (Fig. S1C). These results were further 
confirmed in hepatic PLC (Fig. S2A), neuronal U87 (Fig. S2B), and 
kidney 293T (Fig. S2C) cells. Interestingly, HEV replication was more 
sensitive to gemcitabine with an IC50 of 0.06 μM in 293T cells 
(Fig. S2D). At the same time, ribavirin, widely demonstrated to inhibit 
HEV infection, was used as a positive control (Fig. S1; Fig. S3). 
Furthermore, for the luciferase cell models (GT1 and GT3), the absolute 
luciferase values were presented in Fig. S4. 
3.3. Exogenous supplementation of pyrimidine nucleosides reversed the 
anti-HEV activity of gemcitabine 
As a cytidine analog, gemcitabine depletes the intracellular CTP 
Fig. 1. Drug screening identified gemcita-
bine as a potent inhibitor of HEV replication. 
(A) Huh7 cell based HEV replicon model 
(Huh7-p6-Luc) was treated with 94 broad- 
spectrum antiviral agents at 10 μM. HEV- 
related Gaussia luciferase activity was 
measured 48 h post-treatment. Cell viability 
was determined by MTT. RLU: relative 
luciferase unit. (B) HEV infectious model 
(Huh7-p6) was treated with the 23 drugs 
selected from the primary screening at 10 
μM for 48 h. Viral RNA was quantified by 
qRT-PCR. Data were normalized to the 
DMSO vehicle control (set as 1) and pre-
sented in heatmap or dot plots.   
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(Heinemann et al., 1995). We investigated whether exogenous supple-
mentation of pyrimidine nucleosides could affect the anti-HEV activity 
of gemcitabine. Addition of cytidine, uridine, CTP, or UTP 
dose-dependently reversed the antiviral activity of gemcitabine in HEV 
replicon, and 200 μM of these nucleosides completely blocked the 
antiviral activity of gemcitabine (Fig. 3A). This effect was confirmed in 
the HEV infectious model and significantly reversed the antiviral ac-
tivity of gemcitabine albeit to a less extent (Fig. 3B). In contrast, py-
rimidine nucleosides had no effect on the anti-HEV activity of IFNα 
(Fig. S5). Intriguingly, adding these nucleosides alone hardly affects 
HEV replication (Fig. 3), suggesting that depletion of the pyrimidine 
nucleosides per se does not explain the anti-HEV activity of gemcitabine. 
Fig. 2. Anti-HEV activity of gemcitabine in different cell models. (A) The effects of gemcitabine treatment on viral replication related luciferase activity in Huh7-p6- 
Luc cell model. The untreated group serves as control (set as 1) (n = 18). RLU: relative luciferase unit. (B) The 50% inhibitory concentration (IC50) and 50% cytotoxic 
concentration (CC50) of gemcitabine in Huh7-p6-Luc cell model and Huh7 cell line was calculated using GraphPad Prism 5 software (n = 6–12). (C) Huh7-p6 cell 
model was treated with concentrations of gemcitabine for 48 h. The effects on viral RNA was quantified by qRT-PCR (n = 10). (D) Western blot analysis of HEV 
capsid ORF2 protein level in Huh7-p6 cells treated with gemcitabine for 48 h. The uninfected group (mock) serves as a negative control, and the infected but 
untreated group serves as a positive control (set as 1) (n = 4). (E) Huh7 cell based genotype 1 HEV replicon was treated with gemcitabine for 24, 48 or 72 h and viral 
replication related luciferase activity was measured (n = 10). Data are presented as means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
Fig. 3. Supplement of exogenous pyrimidine nucleosides reversed the anti-HEV effect of gemcitabine. (A) HEV replication related Gaussia luciferase activity in 
Huh7-p6-Luc cells was measured after 72 h of treatment with 5 μM gemcitabine by adding exogenous cytidine, uridine, CTP, or UTP (n = 9–12). (B) HEV RNA in 
Huh7-p6 cells was quantified by qRT-PCR after 48 h of treatment with 5 μM gemcitabine by adding 200 μM exogenous cytidine, uridine, CTP, or UTP (n = 4–10). 
Data were normalized to the untreated control (set as 1). RLU: relative luciferase unit. Data are presented as means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
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3.4. Gemcitabine activates interferon-like response 
We and others have previously found that nucleoside synthesis 
pathways crosstalk with cellular innate immunity. Several nucleosides 
analogs are capable to activate the transcription of antiviral interferon- 
stimulated genes (ISGs), although the underlying mechanisms remain 
unknown (Lucas-Hourani et al., 2013; Pan et al., 2012; Shin et al., 2018; 
Wang et al., 2016c). ISGs as the ultimate antiviral effectors are usually 
activated by interferons. Upon binding to receptors, interferons initiate 
the Janus kinase signal transducer and activator of transcription 
(JAK-STAT) cascade to recruit the ISGF3 complex, which binds to ISRE 
motifs in the nucleus to induce ISG transcription (Xu et al., 2017). 
Similar to IFNα treatment, we found that treatment with different con-
centrations of gemcitabine dose-dependently activated the transcription 
of a panel of ISGs. Particularly, 20 μM of gemcitabine resulted in over a 
hundredfold increase of ISG15 and more than tenfold increase of MX1, 
IFIT1, or DDX58 gene expression (Fig. 4A, Fig. S6). In an ISRE reporter 
mimicking interferon response, gemcitabine robustly triggered the 
transcriptional activity indicated by increased luciferase activity 
(Fig. 4B). For instance, treatment with 20 μM of gemcitabine for 72 h 
resulted in a 3.9 ± 0.2 (mean ± SEM, n = 15, p < 0.0001) -fold increase 
of ISRE related luciferase activity. Thus, similar to interferons, gemci-
tabine is capable to trigger the antiviral innate immune response. 
3.5. Supplementation of pyrimidine nucleosides abrogates gemcitabine- 
induced innate immune response 
As addition of pyrimidine nucleosides reversed the anti-HEV effects 
of gemcitabine (Fig. 3), we further tested the effect on the innate im-
mune response. Supplementation of cytidine or uridine (200 μM) 
significantly abrogated gemcitabine-triggered induction of ISRE activity 
and ISG transcription (Fig. 5A). Among the tested ISGs, except for ISG15, 
the induction of others including MX1, IFIT1, DDX58, CXCL10, and 
STAT1 was significantly attenuated (Fig. 5B). In contrast, cytidine and 
uridine had no effect on IFNα induced ISRE activation and ISG tran-
scription (Fig. S7). These results suggest that gemcitabine triggers 
interferon-like antiviral response, but through distinct mechanisms as 
compared to IFNα. 
3.6. Gemcitabine activates Janus kinase-independent STAT1 
phosphorylation 
In the classical interferon pathway, Janus kinases phosphorylate 
STATs to initiate the response. Interestingly, gemcitabine dramatically 
enhanced the protein expression of STAT1, in particular at the 
phosphorylation level, which is a hallmark of interferon response. 
Treatment with 10 μM gemcitabine increased STAT1 and pSTAT1 pro-
tein levels up to 3.4 ± 0.9 (mean ± SEM, n = 5, p < 0.01) and 2.2 ± 0.2 
(mean ± SEM, n = 5, p < 0.01) -fold, respectively (Fig. 6A). As expected, 
blocking the function of Janus kinases by JAK inhibitor 1 almost 
completely reversed IFNα induced STAT1 phosphorylation, ISRE acti-
vation, ISG transcription, and anti-HEV activity. In contrast, JAK in-
hibitor 1 hardly affected the functions of gemcitabine in this respect 
(Fig. 6B–E). These results further confirm a non-canonical mechanism- 
of-action of gemcitabine in triggering interferon-like antiviral response. 
3.7. STAT1 is essentially required for the action of gemcitabine 
Although Janus kinases are not required, the activation of STAT1 
phosphorylation by gemcitabine is intriguingly prominent (Fig. 6). To 
dissect the functional implication, we used STAT1 knockout Huh7 cells 
(Fig. 7A). In STAT1− /− compared to wild type Huh7 cells, both IFNα and 
gemcitabine failed to trigger ISG transcription (Fig. 7B) and lost the anti- 
HEV activity (Fig. 7C). Therefore, STAT1 phosphorylation is function-
ally required for the anti-HEV action of gemcitabine. 
3.8. Gemcitabine antagonizes ribavirin and MPA, but partially synergizes 
IFNα 
The nucleoside analogs, ribavirin and MPA targeting purine nucle-
oside synthesis, have been widely demonstrated to inhibit HEV infection 
(Wang et al., 2014). Surprisingly, combination with gemcitabine an-
tagonizes the anti-HEV effects of ribavirin (Fig. S8A) and MPA 
(Fig. S8B). In contrast, although not with other concentrations, 
combining 10 μM gemcitabine with 10 IU IFNα resulted in a mild syn-
ergistic effect (Fig. 8A). This was mechanistically supported by the 
enhanced transcription of ISGs (Fig. 8B). 
4. Discussion 
In approximately 80% of patients treated, ribavirin is effective for 
treating chronic hepatitis E. However, treatment failure has been 
frequently reported, probably attributed to resistance development or 
poor tolerance (Debing et al., 2016). The substantial side effects limit 
ribavirin applications in pregnant women, young children, and elderly 
patients. Thus, great efforts have been dedicated to looking for new 
anti-HEV drugs. For example, sofosbuvir as a direct-acting antiviral 
against hepatitis C virus (HCV) has been widely tested for treating 
chronic hepatitis E. Unfortunately, both experimental and clinical re-
sults are contradictive and inconclusive (Dao Thi et al., 2016; Donnelly 
Fig. 4. Gemcitabine activates an interferon-like response. (A) Gene expression of ISGs in Huh7-p6 cells was quantified by qRT-PCR after treatment with gemcitabine 
for 48 h (n = 4). (B) Analysis of ISRE related firefly luciferase activity in Huh7-ISRE-Luc cells treated with gemcitabine or IFNα for 72 h (n = 15–20). Data were 
normalized to the untreated control (set as 1). Data are presented as means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
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et al., 2017; Wang et al., 2016a). As it is highly optimized to target HCV 
polymerase, sofosbuvir is likely not potent against HEV (Kamar et al., 
2017; Wang et al., 2016b). In contrast to empirically testing individual 
candidates, we hypothesize that high-throughput drug screening shall 
enable systematic and unbiased identification of potential anti-HEV 
drugs. We have recently screened a library comprising of over 1000 
FDA-approved drugs, and identified the anti-histamine drug deptropine 
inhibiting HEV in cell culture models (Qu et al., 2019). Although dep-
tropine has been widely prescribed for treating asthmatic symptoms in 
the past, it is currently rarely used in patients because of severe side 
effects (Vaessen and Koopmans, 1992). 
To increase the probability of identifying new anti-HEV agent that 
can immediately treat patients, this study screened a library of known 
safe-in-human broad-spectrum antiviral agents. These compounds have 
been proven to inhibit multiple viruses, and have been used in the clinic 
or passed phase I trials (Andersen et al., 2020; Ianevski et al., 2018). In 
this study, we identified several candidates with novel activities agents 
HEV, but we focused on gemcitabine. As a chemotherapeutic agent with 
Fig. 5. Supplement of exogenous cytidine or uridine abrogated gemcitabine-induced interferon-like response. (A) ISRE related firefly luciferase activity in Huh7- 
ISRE-Luc cells was measured after 72 h of treatment with gemcitabine by adding 200 μM exogenous cytidine or uridine (n = 5–10). (B) Gene expression of ISGs 
in Huh7 cells was quantified by qRT-PCR after 24 h treatment with 5 μM gemcitabine by adding 200 μM exogenous cytidine or uridine (n = 6). RLU: relative 
luciferase unit. Data were normalized to the untreated control (set as 1). Data are presented as means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
Fig. 6. JAK inhibitor 1 does not affect gemcitabine-induced interferon-like response and anti-HEV activity. (A) Western blot analysis of total STAT1 or phos-
phorylated STAT1 (pSTAT1) expression in Huh7 cells treated with indicated concentrations of gemcitabine or IFNα for 48 h. β-actin served as an internal reference (n 
= 3–5). (B) Western blot analysis of STAT1 and phosphorylated STAT1 (pSTAT1) expression in Huh7 cells treated with gemcitabine (10 μM) or IFNα (1000 IU/mL) 
and/or JAK inhibitor 1 (10 μM) for 48 h (n = 6). (C) Analysis of ISRE related firefly luciferase activity in Huh7-ISRE-Luc cells treated with gemcitabine or IFNα (1000 
IU/mL) and/or JAK inhibitor 1 (10 μM) for 72 h (n = 14–16). (D) qRT-PCR analysis of ISGs in Huh7 cells treated with gemcitabine (10 μM) or IFNα (1000 IU/mL) 
and/or JAK inhibitor 1 (10 μM) for 48 h (n = 6). (E) qRT-PCR analysis of HEV RNA in Huh7-p6 cells treated with gemcitabine (10 μM) or IFNα (1000 IU/mL) and/or 
JAK inhibitor 1 (10 μM) for 48 h (n = 6). RLU: relative luciferase unit. Data were normalized to the untreated control (set as 1). Data are presented as means ± SEM. 
(*P < 0.05; **P < 0.01; ***P < 0.001). 
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generic versions widely available, gemcitabine has been extensively 
used to treat many types of cancer (Cerqueira et al., 2007; Zhang et al., 
2019). It is on the list of essential medicines of WHO, among the safest 
and most effective medicines needed in healthcare. In experimental 
models, gemcitabine has been reported to inhibit a broad range of RNA 
viruses including enterovirus with an estimated IC50 of ~5 μM (Lee 
et al., 2017), human rhinovirus with IC50 from 0.81 to 1.92 μM for 
different virus strains (Song et al., 2017), HCV (IC50 of 12 nM) (Beran 
et al., 2012), influenza a (Denisova et al., 2012), HIV (Clouser et al., 
2012), and MERS-CoV and SARS-CoV with micromolar IC50s (1.2 μM 
and 4.9 μM, respectively) (Dyall et al., 2014) and ZIKA virus (Kuivanen 
et al., 2017). Furthermore, various studies have been reported the broad 
antiviral activity of gemcitabine in animal models, such as infected with 
human rhinovirus (Song et al., 2017), leukemia virus (Clouser et al., 
2011) or HIV-1 (Clouser et al., 2012). 
In this study, we have demonstrated potent anti-HEV activity of 
gemcitabine in multiple cell models with both genotype 1 and 3 strains 
that are causing major clinical burden. These results support the po-
tential of clinical application, in particular for treating HEV infected 
cancer patients. In this study, the IC50 of gemcitabine in inhibiting HEV 
was 0.42 μM. This concentration exerting anti-HEV activity in our 
models is easily achievable in cancer patients treated with gemcitabine 
(Keith et al., 2003). Cancer patients, especially when treated with 
chemotherapy or radiotherapy, have a weakened immune system. They 
are prone to infections with worse outcomes (Hotchkiss and Moldawer, 
2014). Chronic HEV infection has been frequently reported in cancer 
patients, but many of them were not treated with antiviral therapy. For 
ribavirin treated individuals, a subset of patients did not tolerate the 
medication or failed to clear HEV (Fuse et al., 2015; Protin et al., 2019; 
Tavitian et al., 2010; von Felden et al., 2019). Our results open a unique 
opportunity for these patients that gemcitabine may simultaneously 
combat the cancer and the virus. Of note, a recent study has nicely 
demonstrated HEV infection in primary human hepatocytes (Todt et al., 
2020). Another recent study has shown HEV infection in human stem 
cell-derived hepatocyte-like cells (Dao Thi et al., 2020). There are also 
multiple animal models available for HEV (Corneillie et al., 2019). In 
this study, we did not further validate our findings in these emerging 
models due to the lacking of essential techniques and expertise, but 
these models highly valuable for HEV drug development. 
The primary anti-cancer mechanism of gemcitabine is depletion of 
pyrimidine nucleosides to block DNA synthesis, thereby killing prolif-
erating cancer cells (Heinemann et al., 1995). This explains the antiviral 
activity at least against some viruses such as enterovirus and rhinovirus 
that supplementation of pyrimidine nucleosides reverses the effect of 
gemcitabine (Lee et al., 2017; Song et al., 2017). Similarly, we also 
found that exogenously adding pyrimidine nucleosides largely abro-
gated the anti-HEV activity of gemcitabine. Surprisingly, pyrimidine 
nucleosides alone did not affect HEV replication. In contrast, we previ-
ously found that adding purine nucleosides enhanced HEV replication 
(Wang et al., 2016c). Thus, the mechanisms of how nucleotide biosyn-
thesis regulates viral infection are highly context-dependent, namely the 
type of targeted virus and the type of affected nucleotide. Based on the 
results from this study, we postulate that the intracellular level of py-
rimidine nucleosides per se does not affect HEV replication, but indi-
rectly mediates the antiviral action of gemcitabine. 
We and other groups have extensively demonstrated that some 
nucleoside analogs are capable of activating cellular innate immunity, in 
particular ISG induction (Chung et al., 2016; Lucas-Hourani et al., 2013; 
Fig. 7. STAT1 knockout completely abrogated gemcitabine-induced ISG transcription and anti-HEV activity. (A) Western blot analysis of STAT1 and phosphorylated 
STAT1 (pSTAT1) expression in WT and STAT1− /− Huh7 cells. (B) qRT-PCR analysis of ISGs in WT and STAT1− /− Huh7 cells treated with gemcitabine (10 μM) or 
IFNα (1000 IU/mL) for 24 h (n = 6). (C) qRT-PCR analysis of HEV RNA in Huh7-p6 and Huh7-STAT1− /− -p6 cells treated with gemcitabine (10 μM) or IFNα (1000 IU/ 
mL) for 48 h (n = 6). Data were normalized to the untreated control (set as 1). Data are presented as means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
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Pan et al., 2012; Wang et al., 2016c; Yeo et al., 2015). Similar to IFNα 
treatment, we found that gemcitabine effectively activated ISRE tran-
scriptional activity and ISG expression. Consistently, supplementation of 
pyrimidine nucleosides blocked this interferon-like response. To our 
knowledge, there is no evidence that nucleosides can directly regulate 
the production of interferon cytokines. A plethora of recent studies have 
reported a variety of non-canonical pathways activating ISG transcrip-
tion, but their mechanisms remain largely elusive (Wang et al., 2017). 
Although intuitive, we speculate that lowering intracellular level of 
pyrimidine nucleosides may act as a sensor of pathogen invasion, and 
thereby signal host cells to initiate defense machinery. 
Classically, interferon activates Janus kinases to phosphorylate 
STATs, which subsequently recruits the ISGF3 complex to drive ISG 
transcription (Xu et al., 2017). Similar to IFNα treatment, we observed 
robust activation of STAT1 phosphorylation by gemcitabine, which is a 
hallmark of the antiviral interferon response. As expected, blocking 
Janus kinases by pharmacological inhibitor completely abrogated the 
antiviral activity of IFNα. In contrast, Janus kinase inhibitor hardly 
affected gemcitabine triggered STAT1 phosphorylation, ISRE tran-
scription, ISG expression, and anti-HEV activity. These results 
concretely confirm a non-canonical action of gemcitabine in triggering 
interferon-like response independent of Janus kinases. Using 
loss-of-function assay, we demonstrated that STAT1 is essentially 
required for the antiviral function of gemcitabine. Nevertheless, we still 
do not have a mechanistic clue how gemcitabine can activate STAT1 
phosphorylation dispensable of Janus kinases, which deserves future 
investigation. 
In summary, by screening a library of known safe-in-human broad- 
spectrum antiviral agents, we identified gemcitabine as a potent inhib-
itor against HEV infection. It functions by triggering interferon-like 
response through STAT1 phosphorylation but independent of Janus ki-
nases. This represents a non-canonical antiviral mechanism utilizing the 
innate defense machinery overlapping with the interferon pathway, but 
is distinct from the classical interferon response. As a widely used anti- 
cancer drug, gemcitabine is extremely appealing for treating HEV 
infected cancer patients that will likely lead to simultaneous anti-cancer 
and antiviral effects. Whether gemcitabine is also applicable for treating 
hepatitis E in non-cancer patients remains to be carefully assessed, 
particularly considering the potential side effects as a chemotherapeutic 
agent. 
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Fig. 8. The combinatory effects of gemcitabine with IFNα on anti-HEV activity and ISG transcription. (A) The antiviral effects of gemcitabine in combination with 
IFNα were analyzed by MacSynergyII model. The three-dimensional surface plot represents the differences (within 95% confidence interval) between actual 
experimental effects and theoretical additive effects of the combination at various concentrations (n = 4). (B) qRT-PCR analysis of ISGs in Huh7 cells treated with 
gemcitabine (10 μM) and/or IFNα (10 IU/mL) (n = 8). RLU: relative luciferase unit. Data were normalized to the untreated control (set as 1). Data are presented as 
means ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001). 
Y. Li et al.                                                                                                                                                                                                                                        
Antiviral Research 184 (2020) 104967
9
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.antiviral.2020.104967. 
References 
Andersen, P.I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjoras, M., 
Telling, K., Lutsar, I., Dumpis, U., Irie, Y., Tenson, T., Kantele, A., Kainov, D.E., 2020. 
Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. 
Infect. Dis. 93, 268–276. 
Beran, R.K., Sharma, R., Corsa, A.C., Tian, Y., Golde, J., Lundgaard, G., Delaney, W.E.t., 
Zhong, W., Greenstein, A.E., 2012. Cellular growth kinetics distinguish a cyclophilin 
inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus. PloS 
One 7, e30286. 
Cerqueira, N.M., Fernandes, P.A., Ramos, M.J., 2007. Understanding ribonucleotide 
reductase inactivation by gemcitabine. Chemistry 13, 8507–8515. 
Chung, D.H., Golden, J.E., Adcock, R.S., Schroeder, C.E., Chu, Y.K., Sotsky, J.B., 
Cramer, D.E., Chilton, P.M., Song, C., Anantpadma, M., Davey, R.A., Prodhan, A.I., 
Yin, X., Zhang, X., 2016. Discovery of a broad-spectrum antiviral compound that 
inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent 
antiviral state. Antimicrob. Agents Chemother. 60, 4552–4562. 
Clouser, C.L., Holtz, C.M., Mullett, M., Crankshaw, D.L., Briggs, J.E., Chauhan, J., 
VanHoutan, I.M., Patterson, S.E., Mansky, L.M., 2011. Analysis of the ex vivo and in 
vivo antiretroviral activity of gemcitabine. PloS One 6, e15840. 
Clouser, C.L., Holtz, C.M., Mullett, M., Crankshaw, D.L., Briggs, J.E., O’Sullivan, M.G., 
Patterson, S.E., Mansky, L.M., 2012. Activity of a novel combined antiretroviral 
therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrob. 
Agents Chemother. 56, 1942–1948. 
Corneillie, L., Banda, D.H., Meuleman, P., 2019. Animal Models for Hepatitis E Virus. 
Viruses 11.  
Dao Thi, V.L., Debing, Y., Wu, X., Rice, C.M., Neyts, J., Moradpour, D., Gouttenoire, J., 
2016. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an 
additive effect when combined with ribavirin. Gastroenterology 150, 82–85 e84. 
Dao Thi, V.L., Wu, X., Belote, R.L., Andreo, U., Takacs, C.N., Fernandez, J.P., Vale- 
Silva, L.A., Prallet, S., Decker, C.C., Fu, R.M., Qu, B., Uryu, K., Molina, H., Saeed, M., 
Steinmann, E., Urban, S., Singaraja, R.R., Schneider, W.M., Simon, S.M., Rice, C.M., 
2020. Stem cell-derived polarized hepatocytes. Nat. Commun. 11, 1677. 
Debing, Y., Gisa, A., Dallmeier, K., Pischke, S., Bremer, B., Manns, M., Wedemeyer, H., 
Suneetha, P.V., Neyts, J., 2014. A mutation in the hepatitis E virus RNA polymerase 
promotes its replication and associates with ribavirin treatment failure in organ 
transplant recipients. Gastroenterology 147, 1008–1011 e1007; quiz e1015-1006.  
Debing, Y., Moradpour, D., Neyts, J., Gouttenoire, J., 2016. Update on hepatitis E 
virology: implications for clinical practice. J. Hepatol. 65, 200–212. 
Denisova, O.V., Kakkola, L., Feng, L., Stenman, J., Nagaraj, A., Lampe, J., Yadav, B., 
Aittokallio, T., Kaukinen, P., Ahola, T., Kuivanen, S., Vapalahti, O., Kantele, A., 
Tynell, J., Julkunen, I., Kallio-Kokko, H., Paavilainen, H., Hukkanen, V., Elliott, R. 
M., De Brabander, J.K., Saelens, X., Kainov, D.E., 2012. Obatoclax, 
saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. 
Chem. 287, 35324–35332. 
Donnelly, M.C., Imlach, S.N., Abravanel, F., Ramalingam, S., Johannessen, I., Petrik, J., 
Fraser, A.R., Campbell, J.D., Bramley, P., Dalton, H.R., Hayes, P.C., Kamar, N., 
Simpson, K.J., 2017. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV 
viremia and restore reactive T cells in a HEV/HCV Co-infected liver transplant 
recipient. Gastroenterology 152, 300–301. 
Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., 
Johnson, R.F., Olinger Jr., G.G., Jahrling, P.B., Laidlaw, M., Johansen, L.M., Lear- 
Rooney, C.M., Glass, P.J., Hensley, L.E., Frieman, M.B., 2014. Repurposing of 
clinically developed drugs for treatment of Middle East respiratory syndrome 
coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4893. 
Fuse, K., Matsuyama, Y., Moriyama, M., Miyakoshi, S., Shibasaki, Y., Takizawa, J., 
Furukawa, T., Fuse, I., Matsumura, H., Uchida, S., Takahashi, Y., Kamimura, K., 
Abe, H., Suda, T., Aoyagi, Y., Sone, H., Masuko, M., 2015. Late onset post-transfusion 
hepatitis E developing during chemotherapy for acute promyelocytic leukemia. 
Intern Med 54, 657–661. 
Haagsma, E.B., Riezebos-Brilman, A., van den Berg, A.P., Porte, R.J., Niesters, H.G., 
2010. Treatment of chronic hepatitis E in liver transplant recipients with pegylated 
interferon alpha-2b. Liver Transplant. 16, 474–477. 
Hakim, M.S., Wang, W., Bramer, W.M., Geng, J., Huang, F., de Man, R.A., 
Peppelenbosch, M.P., Pan, Q., 2017. The global burden of hepatitis E outbreaks: a 
systematic review. Liver Int. 37, 19–31. 
Heinemann, V., Schulz, L., Issels, R.D., Plunkett, W., 1995. Gemcitabine: a modulator of 
intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol. 22, 11–18. 
Hotchkiss, R.S., Moldawer, L.L., 2014. Parallels between cancer and infectious disease. 
N. Engl. J. Med. 371, 380–383. 
Ianevski, A., Zusinaite, E., Kuivanen, S., Strand, M., Lysvand, H., Teppor, M., Kakkola, L., 
Paavilainen, H., Laajala, M., Kallio-Kokko, H., Valkonen, M., Kantele, A., Telling, K., 
Lutsar, I., Letjuka, P., Metelitsa, N., Oksenych, V., Bjoras, M., Nordbo, S.A., 
Dumpis, U., Vitkauskiene, A., Ohrmalm, C., Bondeson, K., Bergqvist, A., 
Aittokallio, T., Cox, R.J., Evander, M., Hukkanen, V., Marjomaki, V., Julkunen, I., 
Vapalahti, O., Tenson, T., Merits, A., Kainov, D., 2018. Novel activities of safe-in- 
human broad-spectrum antiviral agents. Antivir. Res. 154, 174–182. 
Kamar, N., Abravanel, F., Garrouste, C., Cardeau-Desangles, I., Mansuy, J.M., 
Weclawiak, H., Izopet, J., Rostaing, L., 2010a. Three-month pegylated interferon- 
alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. 
Nephrol. Dial. Transplant. 25, 2792–2795. 
Kamar, N., Rostaing, L., Abravanel, F., Garrouste, C., Esposito, L., Cardeau-Desangles, I., 
Mansuy, J.M., Selves, J., Peron, J.M., Otal, P., Muscari, F., Izopet, J., 2010b. 
Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver 
transplantation. Clin. Infect. Dis. 50, e30–33. 
Kamar, N., Selves, J., Mansuy, J.M., Ouezzani, L., Peron, J.M., Guitard, J., Cointault, O., 
Esposito, L., Abravanel, F., Danjoux, M., Durand, D., Vinel, J.P., Izopet, J., 
Rostaing, L., 2008. Hepatitis E virus and chronic hepatitis in organ-transplant 
recipients. N. Engl. J. Med. 358, 811–817. 
Kamar, N., Wang, W., Dalton, H.R., Pan, Q., 2017. Direct-acting antiviral therapy for 
hepatitis E virus? Lancet Gastroenterol Hepatol 2, 154–155. 
Keith, B., Xu, Y., Grem, J.L., 2003. Measurement of the anti-cancer agent gemcitabine in 
human plasma by high-performance liquid chromatography. J Chromatogr B Analyt 
Technol Biomed Life Sci 785, 65–72. 
Kuivanen, S., Bespalov, M.M., Nandania, J., Ianevski, A., Velagapudi, V., De 
Brabander, J.K., Kainov, D.E., Vapalahti, O., 2017. Obatoclax, saliphenylhalamide 
and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular 
signaling, transcription and metabolism. Antivir. Res. 139, 117–128. 
Lee, K., Kim, D.E., Jang, K.S., Kim, S.J., Cho, S., Kim, C., 2017. Gemcitabine, a broad- 
spectrum antiviral drug, suppresses enterovirus infections through innate immunity 
induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. 
Oncotarget 8, 115315–115325. 
Li, P., Liu, J., Li, Y., Su, J., Ma, Z., Bramer, W.M., Cao, W., de Man, R.A., 
Peppelenbosch, M.P., Pan, Q., 2020. The global epidemiology of hepatitis E virus 
infection: a systematic review and meta-analysis. Liver Int. Jul;40(7), 1516–1528. 
Lucas-Hourani, M., Dauzonne, D., Jorda, P., Cousin, G., Lupan, A., Helynck, O., 
Caignard, G., Janvier, G., Andre-Leroux, G., Khiar, S., Escriou, N., Despres, P., 
Jacob, Y., Munier-Lehmann, H., Tangy, F., Vidalain, P.O., 2013. Inhibition of 
pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. 
PLoS Pathog. 9, e1003678. 
Pan, Q., de Ruiter, P.E., Metselaar, H.J., Kwekkeboom, J., de Jonge, J., Tilanus, H.W., 
Janssen, H.L., van der Laan, L.J., 2012. Mycophenolic acid augments interferon- 
stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in 
vivo. Hepatology 55, 1673–1683. 
Pischke, S., Hardtke, S., Bode, U., Birkner, S., Chatzikyrkou, C., Kauffmann, W., Bara, C. 
L., Gottlieb, J., Wenzel, J., Manns, M.P., Wedemeyer, H., 2013. Ribavirin treatment 
of acute and chronic hepatitis E: a single-centre experience. Liver Int. 33, 722–726. 
Protin, C., Abravanel, F., Alric, L., Tavitian, S., Oberic, L., Izopet, J., Martin-Blondel, G., 
Ysebaert, L., 2019. Ribavirin for chronic hepatitis E virus infection in ibrutinib- 
exposed patients. Open Forum Infect Dis 6, ofz345. 
Qu, C., Li, Y., Li, Y., Yu, P., Li, P., Donkers, J.M., van de Graaf, S.F.J., de Man, R.A., 
Peppelenbosch, M.P., Pan, Q., 2019. FDA-drug screening identifies deptropine 
inhibiting hepatitis E virus involving the NF-kappaB-RIPK1-caspase axis. Antivir. 
Res. 170, 104588. 
Rostaing, L., Izopet, J., Baron, E., Duffaut, M., Puel, J., Durand, D., 1995. Treatment of 
chronic hepatitis C with recombinant interferon alpha in kidney transplant 
recipients. Transplantation 59, 1426–1431. 
Shin, H.J., Kim, C., Cho, S., 2018. Gemcitabine and Nucleos(t)ide Synthesis Inhibitors 
Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity. Viruses 10.  
Song, J.H., Kim, S.R., Heo, E.Y., Lee, J.Y., Kim, D.E., Cho, S., Chang, S.Y., Yoon, B.I., 
Seong, J., Ko, H.J., 2017. Antiviral activity of gemcitabine against human rhinovirus 
in vitro and in vivo. Antivir. Res. 145, 6–13. 
Tavitian, S., Peron, J.M., Huynh, A., Mansuy, J.M., Ysebaert, L., Huguet, F., Vinel, J.P., 
Attal, M., Izopet, J., Recher, C., 2010. Hepatitis E virus excretion can be prolonged in 
patients with hematological malignancies. J. Clin. Virol. 49, 141–144. 
Todt, D., Friesland, M., Moeller, N., Praditya, D., Kinast, V., Brüggemann, Y., 
Knegendorf, L., Burkard, T., Steinmann, J., Burm, R., Verhoye, L., Wahid, A., 
Meister, T.L., Engelmann, M., Pfankuche, V.M., Puff, C., Vondran, F.W.R., 
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